Related Experiment Video
Updated: Mar 7, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Lipid-lowering Therapy in Patients With High Cardiovascular Risk: Dose or Combination?
Leonardo Roever1, Giuseppe Biondi-Zoccai2, Sunil V Rao3
1Department of Clinical Research, Federal University of Uberlândia, Uberlândia, Brazil.
Insights
Lifestyle changes and combination therapy effectively reduce cardiovascular risk by lowering low-density lipoprotein cholesterol (LDL-C) levels. These interventions are crucial for preventing atherosclerosis and achieving lipid targets in high-risk patients.
Area of Science:
- Cardiology
- Preventive Medicine
- Metabolic Disorders
Background:
- Cardiovascular disease (CVD) is the primary global cause of mortality.
- Dyslipidemia, characterized by elevated low-density lipoprotein cholesterol (LDL-C), drives atherosclerosis development.
- Managing dyslipidemia is key for cardiovascular event prevention.
Purpose of the Study:
- To evaluate the efficacy of therapeutic lifestyle changes and combination therapy in managing dyslipidemia.
- To assess the impact of interventions on reducing cardiovascular risk.
- To determine if LDL-C targets can be achieved in high-risk populations.
Main Methods:
- Review of therapeutic lifestyle changes including diet, exercise, and weight management.
- Analysis of combination therapy's effect on LDL-C levels.
- Assessment of cardiovascular risk reduction in primary and secondary prevention.
Main Results:
- Therapeutic lifestyle changes significantly reduce cardiovascular risk.
- Combination therapy demonstrated effectiveness in lowering LDL-C.
- Achieved target LDL-C levels in patients with high cardiovascular risk.
Conclusions:
- Lifestyle modifications are fundamental for cardiovascular risk reduction.
- Combination therapy offers a potent strategy for managing dyslipidemia.
- Interventions are effective in achieving therapeutic goals for high-risk individuals.
Abstract:
Cardiovascular disease is the leading cause of death in the world. Dyslipidemia, manifested by elevated low-density lipoprotein cholesterol (LDL-C) levels, is central to the development and progression of atherosclerosis. Dyslipidemia has become a primary target of intervention in strategies for the prevention of cardiovascular events. Therapeutic lifestyle changes, such as increased physical activity, weight loss, smoking cessation, and adoption of a healthier diet, are effectively reducing cardiovascular risk in primary and secondary prevention. The combination therapy lowered LDL-C levels and achieved the LDL-C target in patients with high cardiovascular risk.
Related Concept Videos
Atherosclerosis III: Management
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Coronary Artery Disease IV: Preventive Measures
Hypertension IV: Drug Therapy and Lifestyle Modifications
Cardiovascular Drugs: Classification based on Therapeutic Indications
Drug Dosing: Obese Patients
